Murphy & Mullick Capital Management’s Novartis NVS Stock Holding History

Murphy & Mullick Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$102K	Hold	650	–	–	0.06%	208
2026 Q1	$99.3K	Hold	650	–	–	0.07%	202
2025 Q4	$89.6K	Hold	650	–	–	0.06%	212
2025 Q3	$83.4K	Hold	650	–	–	0.06%	218
2025 Q2	$73.9K	Hold	650	–	–	0.06%	220
2025 Q1	$72.5K	Hold	650	–	–	0.07%	216
2024 Q4	$63.3K	Buy	+650	New	+$69.3K	0.06%	229

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Murphy & Mullick Capital Management's NVS Position: Q2 2026 in Review

Murphy & Mullick Capital Management held its Novartis (NVS) position steady in Q2 2026 at 650 shares worth $102K. The position accounts for 0.06% of the portfolio, ranked #208.

Murphy & Mullick Capital Management first reported a position in NVS in Q4 2024 and has held it in 7 quarters since. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Murphy & Mullick Capital Management held 650 shares of Novartis worth $102K as of Q2 2026.
Murphy & Mullick Capital Management left its Novartis share count unchanged in Q2 2026.
Novartis made up 0.06% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #208 holding.
Murphy & Mullick Capital Management first reported a position in Novartis in Q4 2024 and has held it in 7 quarters since.
1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.